These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 10716323

  • 1. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, Le Doussal JM, Barbet J.
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [Abstract] [Full Text] [Related]

  • 2. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J.
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [Abstract] [Full Text] [Related]

  • 3. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [Abstract] [Full Text] [Related]

  • 4. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E, Kraeber-Bodéré F, Daniel L, Fiche M, Rouvier E, Saï-Maurel C, Thedrez P, Chatal JF, Barbet J.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [Abstract] [Full Text] [Related]

  • 5. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [Abstract] [Full Text] [Related]

  • 6. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten.
    Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E, Barbet J.
    Cancer; 1997 Dec 15; 80(12 Suppl):2618-23. PubMed ID: 9406716
    [Abstract] [Full Text] [Related]

  • 7. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
    Gestin JF, Loussouarn A, Bardiès M, Gautherot E, Gruaz-Guyon A, Saï-Maurel C, Barbet J, Curtet C, Chatal JF, Faivre-Chauvet A.
    J Nucl Med; 2001 Jan 15; 42(1):146-53. PubMed ID: 11197965
    [Abstract] [Full Text] [Related]

  • 8. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [Abstract] [Full Text] [Related]

  • 9. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J.
    J Nucl Med; 2006 Feb 01; 47(2):247-55. PubMed ID: 16455630
    [Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
    Colapinto EV, Zalutsky MR, Archer GE, Noska MA, Friedman HS, Carrel S, Bigner DD.
    Cancer Res; 1990 Mar 15; 50(6):1822-7. PubMed ID: 2407345
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.
    J Nucl Med; 2006 Jul 15; 47(7):1127-35. PubMed ID: 16818947
    [Abstract] [Full Text] [Related]

  • 12. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
    [Abstract] [Full Text] [Related]

  • 13. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, Lorf T, Post S, Wörmann B, Hiddemann W, Ringe B, Becker W.
    Anticancer Res; 1999 Oct 15; 19(4A):2427-32. PubMed ID: 10470170
    [Abstract] [Full Text] [Related]

  • 14. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.
    Li L, Xu HY, Mi L, Bian HJ, Qin J, Xiong H, Feng Q, Wen N, Tian R, Xu LQ, Shen XM, Tang H, Chen ZN.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1238-44. PubMed ID: 16979831
    [Abstract] [Full Text] [Related]

  • 15. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG, Oosterwijk E, Soede AC, Oyen WJ, McBride WJ, Griffiths GL, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [Abstract] [Full Text] [Related]

  • 16. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [Abstract] [Full Text] [Related]

  • 17. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice.
    Buchegger F, Rojas A, Delaloye AB, Vogel CA, Mirimanoff RO, Coucke P, Sun LQ, Raimondi S, Denekamp J, Pèlgrin A.
    Cancer Res; 1995 Jan 01; 55(1):83-9. PubMed ID: 7805046
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
    Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardiès M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
    [Abstract] [Full Text] [Related]

  • 19. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.
    Br J Cancer; 1999 Nov 01; 81(6):972-80. PubMed ID: 10576653
    [Abstract] [Full Text] [Related]

  • 20. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.